Obtenga las últimas noticias sobre las acciones de BioLine Rx con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de BLRX

Últimas noticias sobre

BioLine Rx

BioLineRx Ltd. - American Depositary Shares

BioLine Rx Ltd

Abpro Hldgs

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

BioCardia

BioVie

Curis

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Edesa Biotech

Ernexa Therapeutics

FibroBiologics

Geovax Labs

Imunon

Immuron Limited - American Depositary Shares

Immuron

Kairos Pharma

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Longeveron

Marker Therapeutics

MetaVia

OSR Holdings

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Soligenix

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

BioLine Rx (BLRX) Previsión

Noticias

Beneficios

Opciones

Calificaciones de analistas

Interés en corto

Informe de acciones

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Comments

BioLine Rx Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL